Ethismos’ Mission Is To Prevent and Treat Chronic Pain

Key To Prevention and Treatment of Chronic Pain Is Multi-Modal Modulation of Brain Circuitries That Underlie The Co-Morbidity of Mood and Pain

News Bulletin:

January, 2023

Ethismos Research management was made aware of a currently unknown recruiter purporting availability of Data Entry positions. This is a scam and any individuals presenting said positions should be disregarded and reported immediately. As of January 2023, Ethismos is not yet seeking applicants for open positions.

About

Ethismos Research, Inc. is a clinical stage pharmaceutical/drug development company based in Cambridge, Massachusetts. Ethismos’ new approach to pain targets the acute to chronic pain transition; reduces exposure to opioids in patients with disabling chronic pain; and addresses weaknesses of chronic ketamine for treatment resistant depression.

Ethismos’ Development team includes seasoned management and vendors with 10+ years of experience with the lead molecule, the triple reuptake inhibitor amitifadine.

Our Goal

We are dedicated to discovering and developing safe and effective therapies for prevention of chronic pain, treatment of chronic pain, opioid dose reduction in chronic pain, treatment resistant depression, and substance use disorders.

We welcome you to explore our website and learn more about our research, R&D pipeline, team and related resources.

The Ethismos’ Science focuses on applying its novel therapeutic to solving serious unmet medical needs involving:

  • Prevention of Chronic Pain

  • Treatment of Chronic Musculoskeletal Low Back Pain

Ethismos’ Management

Anthony McKinney, Director
Founder, President & CEO
Former Neurovance, Euthymics, Orexigen, Genzyme, Novazyme, Texas Biotechnology, DuPont Merck

William Pappafotopoulos, Director
CFO
Former Chief financial and admin officer, Neurovance/Euthymics
20+ years in public accounting, President, Milton Financial
Formerly with Johnson & Johnson, IRS

Kimberly Nearing, Director
Venture Partner, BVCF Management, Ltd.
Board of Directors, Bay Helix Group
Board of Directors and Executive Committee, Rostropovich-Vishnevskaya Foundation

Donald R. Kiepert, Director
Executive Chairman & CEO, Seropeutics, LLC
Former President & CEO, Lantheus Medical Imaging
Founder, President, CEO and Chairman, Point Therapeutics

Dr. Robert Dworkin, Director and SAB Member
Univ. of Rochester, Professor of Anesthesiology
Special Employee with FDA; Director of ACTTION, a public-private partnership with FDA on pain
Pain KOL and clinical trial design expert
Has advised 180 pharma/biotech companies on pain